160 related articles for article (PubMed ID: 38438773)
1. CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.
Wang J; Xi YF; Zhao Q; Guo JH; Zhang Z; Zhang MB; Chang J; Wu YQ; Su W
Mol Biol Rep; 2024 Mar; 51(1):385. PubMed ID: 38438773
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
Ito S; Ohga T; Saeki H; Watanabe M; Kakeji Y; Morita M; Yamada T; Maehara Y
Anticancer Res; 2007; 27(5A):3345-53. PubMed ID: 17970080
[TBL] [Abstract][Full Text] [Related]
3. p14ARF deletion and methylation in genetic pathways to glioblastomas.
Nakamura M; Watanabe T; Klangby U; Asker C; Wiman K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 2001 Apr; 11(2):159-68. PubMed ID: 11303791
[TBL] [Abstract][Full Text] [Related]
4. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
6. microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Rezaei T; Hejazi M; Mansoori B; Mohammadi A; Amini M; Mosafer J; Rezaei S; Mokhtarzadeh A; Baradaran B
Eur J Pharmacol; 2020 Dec; 888():173483. PubMed ID: 32810491
[TBL] [Abstract][Full Text] [Related]
7. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
8. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
Bai M; Yu NZ; Long F; Feng C; Wang XJ
Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
[TBL] [Abstract][Full Text] [Related]
9. OCT4 maintains self-renewal and reverses senescence in human hair follicle mesenchymal stem cells through the downregulation of p21 by DNA methyltransferases.
Lu Y; Qu H; Qi D; Xu W; Liu S; Jin X; Song P; Guo Y; Jia Y; Wang X; Li H; Li Y; Quan C
Stem Cell Res Ther; 2019 Jan; 10(1):28. PubMed ID: 30646941
[TBL] [Abstract][Full Text] [Related]
10. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.
Zorniak M; Clark PA; Kuo JS
J Neurosurg; 2015 Jan; 122(1):69-77. PubMed ID: 25361488
[TBL] [Abstract][Full Text] [Related]
11. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma.
Uenogawa K; Hatta Y; Arima N; Hayakawa S; Sawada U; Aizawa S; Yamamoto T; Takeuchi J
Int J Mol Med; 2011 Nov; 28(5):835-9. PubMed ID: 21785817
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between alterations of p16INK4a and p14ARF genes of CDKN2A locus and gastric carcinogenesis].
Tang SH; Yang DH; Luo HS; Yu JP; Shu JC
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):517-21. PubMed ID: 15231134
[TBL] [Abstract][Full Text] [Related]
14. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Feng X; Zhang B; Wang J; Xu X; Lin N; Liu H
Med Oncol; 2011 Mar; 28(1):24-30. PubMed ID: 20221717
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
Shima K; Nosho K; Baba Y; Cantor M; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
Int J Cancer; 2011 Mar; 128(5):1080-94. PubMed ID: 20473920
[TBL] [Abstract][Full Text] [Related]
17. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line.
Frost SJ; Simpson DJ; Clayton RN; Farrell WE
Mol Endocrinol; 1999 Nov; 13(11):1801-10. PubMed ID: 10551774
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type.
Tsujimoto H; Hagiwara A; Sugihara H; Hattori T; Yamagishi H
Pathol Res Pract; 2002; 198(12):785-94. PubMed ID: 12608655
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
